Market capitalization | $3.34m |
Enterprise Value | $-2.05m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.25 |
P/B ratio (TTM) P/B ratio | 0.37 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.49m |
Free Cash Flow (TTM) Free Cash Flow | $-8.11m |
Cash position | $5.39m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:
1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.08 -0.08 |
58%
58%
|
|
EBITDA | -7.41 -7.41 |
35%
35%
|
EBIT (Operating Income) EBIT | -7.49 -7.49 |
36%
36%
|
Net Profit | -7.42 -7.42 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Head office | United States |
CEO | Robert Bitterman |
Employees | 9 |
Founded | 2011 |
Website | www.phiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.